Hepatitis
B Top News Articles |
|
| UK
Health Agency Recommends Approval of Entecavir (Baraclude)
for Treatment of Eligible Patients with Chronic Hepatitis B -
6/24/08 |
| Resistance
to Adefovir (Hepsera) and Lamivudine (Epivir-HBV)
in Chronic Hepatitis B Patients -
6/24/08 |
| Adolescents
May Require Hepatitis B Vaccine Boosters
-
6/20/08
|
| Association
between ALT and HBV DNA Viral Load in Chronic Hepatitis B Patients Treated with
Pegylated Interferon -
6/16/08 |
| Association
between Hepatitis B and C Virus Infection
and Extrahepatic Bile Duct Cancer -
6/16/08 |
| Safety,
Efficacy, and Pharmacokinetics of Adefovir (Hepsera)
in Children and Adolescents with Chronic Hepatitis B
-
6/13/08
|
| Combination
Therapy with Lamivudine (Epivir-HBV) plus
Adefovir (Hepsera) for Chronic
Hepatitis B Prevents Resistance to Both Drugs -
6/10/08 |
| Higher
HBV DNA Levels Linked to Increased Risk of Liver Cirrhosis
in People with Chronic Hepatitis B -
6/10/08 |
| Chronic
Hepatitis B Patients with Normal or Minimally Elevated ALT and Detectable
HBV DNA May Experience Active Liver Disease Progression -
6/06/08 |
| Pegylated
Interferon Alfa-2a (Pegasys) Continues to
Suppress HBV, but Adding Adefovir (Hepsera)
Provides No Extra Benefit in PEG for B Trial
-
6/03/08 |
| High
Maternal HBV Viral Load, but Not HBeAg Status, Predicts Mother-to-child Hepatitis
B Transmission -
5/30/08 |
| FDA
Proposes New Rule to Provide Updated Information on Use of Prescription Drugs
and Biological Products during Pregnancy and Breast-feeding -
5/30/08 |
| Response
to Pegylated Interferon in Adolescents with
Chronic Hepatitis B -
5/23/08 |
| HCV
May Inhibit HBV Replication in HCV-HBV Coinfected
Patients
|
| Tenofovir
(Viread) Demonstrates Good Efficacy and Tolerability
in Hepatitis B Patients with Compensated Liver Cirrhosis
-
5/13/08 |
| Tenofovir
May Be More Effective and Less Expensive than Lamivudine (Epivir-HBV)
and Adefovir (Hepsera) as First-line Treatment
for HBeAg- Chronic Hepatitis B -
5/09/08 |
| Lamivudine
(Epivir-HBV) plus Adefovir (Hepsera)
Is an Effective Regimen for Lamivudine-resistant HBV Patients Who Develop Resistance
to Entecavir (Baraclude) -
5/09/08 |
| Pegylated
Interferon plus Ribavirin Is Effective for Patients with HCV-HBV
Coinfection -
5/09/08 |
| Entecavir
(Baraclude) Produces Greater Decrease in HBV
DNA than Adefovir (Hepsera) in Treatment-naive
HBeAg+ Patients: 96 Week Data from EARLY Study
-
5/06/08 |
| Three
Years of Continuous Entecavir (Baraclude)
in Chinese Patients with Prior Lamivudine (Epivir-HBV)
Failure: Studies ETV-056 and ETV-050 -
5/06/08 |
| Entecavir
(Baraclude) Treatment in Japanese Nucleoside-naive
Chronic Hepatitis B Patients -
5/06/08 |
| R.E.V.E.A.L.-HBV
Study Shows Persistently High Hepatitis B Viral Load Raises the Risk
of Liver Cancer -
4/29/08 |
| Tenofovir
(Viread) Is Effective in Chronic Hepatitis
B Patients with Prior Nucleoside/nucleotide Experience -
4/29/08 |
| European
Commission Approves Tenofovir (Viread) for
Chronic Hepatitis B -
4/29/08 |
| European
Association for the Study of the Liver (EASL)
Meeting Opens in Milan -
4/24/08 |
| Pegasys
Demonstrates Continued Benefits for Chronic Hepatitis B Patients at 4 Year
-
4/24/08 |
| Gilead
Announces 72-Week Data from Pivotal Studies of Tenofovir (Viread)
for Chronic Hepatitis B -
4/24/08 |
| Lamivudine
(Epivir-HBV) Monotherapy versus Lamivudine
plus Adefovir (Hepsera) for Chronic Hepatitis
-
4/11/08 |
| Study
Looks at Impact of Hepatitis B Disease Progression on Quality of Life -
4/04/08 |
| FDA
Grants Orphan Drug Approval of Hepatitis B Immune Globulin
to Prevent Post-transplant Recurrence -
4/04/08 |
| Five-year
Data Show Continued Low Rate of Resistance to Entecavir (Baraclude)
in Chronic Hepatitis B Patients -
3/28/08 |
| Has
the Time Come for Expanded Off-label Use of Combination Treatment for Chronic
Hepatitis B? -
3/21/08 |
| Tenofovir
(Viread) plus Lamivudine (Epivir-HBV)
Appears Effective as Rescue Therapy for Cirrhotic Patients with Resistance to
Adefovir (Hepsera) -
3/21/08 |
| European
Medicines Agency Gives Positive Opinion on Tenofovir (Viread) for Treatment of
Chronic Hepatitis B -
3/21/08 |
| Canadian
Health Officials Warn against Use of Tebivudine (Tyzeka/Sebivo) in Combination
with Interferons -
3/18/08 |
| Occult
Hepatitis B Virus in Individuals without Liver Disease -
3/14/08 |
| Vaccination
Dramatically Cuts Hepatitis B in Italy, but Concerns Remain -
3/11/08 |
| Hepatitis
B: Reflections on the Current Approach to Antiviral Therapy -
3/07/08 |
| Adefovir
(Hepsera) for Treatment of Patients with Chronic Hepatitis B Resistant to Lamivudine
(Epivir-HBV) -
3/04/08 |
| Likelihood
of Adefovir (Hepsera) Resistance in Nucleoside-naive Hepatitis B Patients
-
2/29/08 |
| HBeAg
and HBV DNA Predict Outcomes of Pegylated Interferon Therapy for Chronic Hepatitis
B -
2/19/08 |
| Tenofovir
(Viread) Is Effective after Adefovir (Hepsera), but Not Vice Versa -
2/01/08 |
| Lamivudine
Prevents HBV Reactivation in Immunosuppressed Patients -
1/29/08 |
| Disease
Progression in Patients with HBeAg-negative Chronic Hepatitis B -
1/29/08 |
| Hepatitis
B Exacerbation May Occur in Women after Giving Birth -
1/25/08 |
| Overview
of the Natural History of Chronic Hepatitis B -
1/18/08 |
| Long-term
Response to Lamivudine (Epivir-HBV) in Children with Chronic Hepatitis -
1/18/08 |
| Relation
between HBV "X" Gene Integration and Development of Hepatocellular Carcinoma
-
1/14/08 |
| Once-daily
Clevudine Demonstrates Early HBV Suppression and Biochemical Improvement in Hepatitis
B Patients with Liver Cirrhosis -
1/14/08 |
| Extended
Duration Pegylated Interferon Alfa-2a (Pegasys) for Patients with HBeAg Negative
Chronic Hepatitis B -
1/11/08 |
| HBV
Viral Load at Week 4 of Lamivudine (Epivir-HBV) Treatment Predicts Response at
5 Years -
1/08/08 |
| Two
Studies Show Telbivudine (Tyzeka) Is Superior to Lamivudine (Epivir-HBV) for Chronic
Hepatitis B -
1/08/08 |
| Telbivudine
(Tyzeka) Superior to Adefovir (Hepsera) at 52 Weeks -
1/04/08 |
| Clinical
Significance of Persistently Normal ALT in Chronic Hepatitis B Patients -
1/04/08 |
| Individuals
with Hepatitis B Virus Genotype C Experience HBeAg Clearance Later and Less Often
-
12/14/07 |
|
FDA-approved
Treatments
